EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, Biological Evaluation, and In Silico Studies of Novel Furo[2,3‐ d ]pyrimidine Derivatives as EGFR Inhibitors With Potential Antitumor Activity

Samar I Faggal, Walid E Elgammal iD, Amr Sonousi, Amr M Abdou, Soha O Hassanin, Rasha A Hassan iD

Archiv der Pharmazie · 2025-11 · 358 (11)

DOI: 10.1002/ardp.70146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 21.11.2025. Verfasst von Samar I Faggal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pyrimidines, Drug Design, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the pursuit of developing targeted therapies, novel furo[2,3‐ d ]pyrimidine compounds were synthesized, incorporating the characteristic structural features of EGFR tyrosine kinase inhibitors. These compounds were screened for antiproliferative effects across 60 human cancer cell lines. Compound 3f was the most effective. Further evaluation at five concentrations to determine its GI 50 , TGI, and LC 50 . In vitro studies were conducted to evaluate its impact on EGFR signaling, cell cycle progression, apoptosis induction, and caspase‐3 activation in T‐47D cells. Compound 3f showed greater selectivity toward cancerous T‐47D cells over normal breast cells (MCF10a). Notably, compound 3f displayed potent EGFR inhibition at submicromolar levels, with an IC 50 of 0.121 ± 0.004 μM, which was comparable to the reference inhibitor, erlotinib. Further investigations revealed that compound 3f caused cell cycle arrest at the G2/M phase in T‐47D cells. Apoptosis analysis confirmed that compound 3f induced cell death through programmed cell death, with a nearly 19‐fold increase in total apoptosis. This apoptotic mechanism was validated by a substantial rise in active caspase‐3 levels. Molecular docking studies showed favorable binding of compound 3f within the EGFR active site. Molecular dynamics simulations further confirmed the stability of compound 3f within the active site over a 100‐ns simulation period, supporting its sustained interaction with key residues. Based on predictions of toxicity, compound 3f was predicted to possess a favorable safety profile across 30 potential toxicities. Encouraged by its strong anticancer efficacy and safety profile, compound 3f represents a compelling lead candidate for further development as a targeted treatment for breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPyrimidinesDrug DesignProtein Kinase InhibitorsHumansErbB ReceptorsStructure-Activity RelationshipCell ProliferationApoptosisMolecular Docking SimulationCell Line, TumorDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, Drug

Stichwörter der Autor:innen

EGFRantiproliferative activitycaspase 3furo[2,3‐d]pyrimidinemolecular modeling

Substanzen

ErbB ReceptorsAntineoplastic AgentsPyrimidinesProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Chemistry Department, Faculty of Science (Boys), Al-Azhar University, Nasr City, Cairo, Egypt.
  • University of Hertfordshire hosted by Global Academic Foundation, New Administrative Capital, Cairo, Egypt.
  • Department of Microbiology and Immunology, National Research Centre, Dokki, Giza, Egypt.
  • Biochemistry Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.

ORCID-Profile: Walid E Elgammal, Rasha A Hassan

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Faggal, S. I., Elgammal, W. E., Sonousi, A., Abdou, A. M., Hassanin, S. O., & Hassan, R. A. (2025). Design, Synthesis, Biological Evaluation, and In Silico Studies of Novel Furo[2,3‐ d ]pyrimidine Derivatives as EGFR Inhibitors With Potential Antitumor Activity. Archiv der Pharmazie, 358(11). https://doi.org/10.1002/ardp.70146

Vancouver

Faggal SI, Elgammal WE, Sonousi A, Abdou AM, Hassanin SO, Hassan RA. Design, Synthesis, Biological Evaluation, and In Silico Studies of Novel Furo[2,3‐ d ]pyrimidine Derivatives as EGFR Inhibitors With Potential Antitumor Activity. Archiv der Pharmazie. 2025;358(11). doi:10.1002/ardp.70146

BibTeX
@article{Faggal2025,
  author = {Faggal, Samar I and Elgammal, Walid E and Sonousi, Amr and Abdou, Amr M and Hassanin, Soha O and Hassan, Rasha A},
  title = {Design, Synthesis, Biological Evaluation, and In Silico Studies of Novel Furo[2,3‐ d ]pyrimidine Derivatives as EGFR Inhibitors With Potential Antitumor Activity},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {11},
  doi = {10.1002/ardp.70146}
}
Kostenlos starten →